stockrowNovoCure Limited
NVCR Healthcare Medical Devices
NovoCure Limited’s revenue for fiscal 2025 (year ended December 2025) was $655.4 million, up 8.28% from fiscal 2024.
- Revenue
- +15.7%
- EPS
- +72.9%
- Free cash flow
- +5.54%
- Total debt
- +0.87%
Quarter to September 2026, against a year earlier
Follow NVCR
Alert me
NovoCure Limited (NVCR) EV/Sales
As of 5 November 2026, NovoCure Limited (NVCR) trades at a EV/Sales of 1.8×. Over the past ten years it has ranged from 0.6× (December 2025) to 43.3× (June 2021); the current reading is higher than 9% of that period. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.8× | (54.04%) |
| FY2024 | 3.9× | 67.72% |
| FY2023 | 2.3× | (81.29%) |
| FY2022 | 12.5× | (9.72%) |
| FY2021 | 13.8× | (59.93%) |
| FY2020 | 34.5× | 51.08% |
| FY2019 | 22.8× | 90.20% |
| FY2018 | 12.0× | 24.22% |
| FY2017 | 9.7× | 46.07% |
| FY2016 | 6.6× | (49.53%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 2.2× | 1.68% |
| Jun 2026 | 2.1× | 39.75% |
| Mar 2026 | 1.5× | (14.49%) |
| Dec 2025 | 1.8× | 91.14% |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ENOV Enovis Corporation compare | 1.3× |
| TNDM Tandem Diabetes Care, Inc. compare | 1.3× |
| CNMD CONMED Corporation compare | 1.7× |
| NVCR NovoCure Limited | 1.8× |
| INSP Inspire Medical Systems, Inc. compare | 1.8× |
| AORT Artivion, Inc. compare | 3.2× |
| ESTA Establishment Labs Holdings Inc. compare | 8.7× |
| BFLY Butterfly Network, Inc. compare | 12.5× |
| ALMR Alamar Biosciences, Inc. compare | 15.6× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)